Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 7711 results

  1. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399

    Awaiting development [GID-TA11499] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    Awaiting development [GID-TA11299] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  7. Tiratricol for treating Allan–Herndon–Dudley syndrome ID6217

    Awaiting development [GID-TA11192] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

    NICE guideline
    In development

  9. PICO negative pressure wound dressings for closed surgical incisions (MTG43)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

    Medical technologies guidance
    Last updated
    6 August 2019
    View recommendations

    Sections for MTG43

  10. Endocuff Vision for assisting visualisation during colonoscopy (MTG45)

    Evidence-based recommendations on Endocuff Vision for assisting visualisation during colonoscopy.

    Medical technologies guidance
    Published
    7 June 2019
    View recommendations

    Sections for MTG45

  11. gammaCore for cluster headache (MTG46)

    Evidence-based recommendations on gammaCore for cluster headache.

    Medical technologies guidance
    Published
    3 December 2019
    View recommendations

    Sections for MTG46

  12. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

    Medical technologies guidance
    Published
    23 January 2019
    View recommendations

    Sections for MTG41

  13. UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

    Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.

    Medical technologies guidance
    Last updated
    4 April 2023
    View recommendations

    Sections for MTG42

  14. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)

    Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.

    Medical technologies guidance
    Last updated
    18 September 2019
    View recommendations

    Sections for MTG25

  15. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development [GID-TA11303] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development